Research Article

Prevalence of Extended-Spectrum β-Lactamase-Production among Clinical Gram-Negative Bacilli Isolates in A Tertiary Hospital, Southwest Nigeria

Babatunde Odetoyin
Obafemi Awolowo University, Nigeria
* Corresponding author
Oluwaseun Adewole
University of Ibadan, Nigeria
DOI icon 10.24018/ejmed.2021.3.5.1031

Read Counter
1647

Downloads
531

Citations

Share

Article Sidebar

Submitted 2021-08-24
Published 2021-09-21

Read counter = 1647 times

Table of Contents

Article Main Content

Extended spectrum β-lactamases (ESBLs) have emerged as important mechanisms of antimicrobial resistance to beta-lactam drugs in hospitals, thereby limiting the available treatment options for infections caused by these microorganisms. The objectives of this study were to determine the prevalence of ESBL production among clinical isolates of Gram-negative bacilli from Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria as part of the global efforts to provide information for the containment of the spread of antimicrobial resistance. This is a laboratory-based study of 186 consecutive non-duplicate Gram-negative bacilli (GNB) isolated from diverse clinical samples at the Microbiology laboratory of the hospital after standard aerobic cultures. The isolates were identified by conventional biochemical test scheme and commercial GNB API 20E identification kit. Antimicrobial susceptibility testing (AST) of each isolate was determined by the disk diffusion technique. Isolates presumptively identified as ESBL producers from the AST assay were confirmed by the combination disks method. Escherichia coli (n=43; 23.1%) predominated among the organisms, followed by Enterobacter spp (n=23; 12.4%) and Klebsiella spp (n=22; 11.8%). Most of the organisms (95.7%) were resistant to tetracycline and ampicillin, but the least resistance (4.3%) was exhibited to imipenem. Fifty-eight (31.2%) isolates were ESBL producers with a preponderance of E. coli (n=15; 25.9%). The ESBL producers were commonly isolated from urine samples (n=31; 53.4%), and were significantly more resistant to levofloxacin, ciprofloxacin, nalidixic acid, gentamicin, augmentin, cefepime, ceftriaxone, ceftazidime and cefotaxime (p<0.05). This study has highlighted the therapeutic implications of the presence of EBSL in clinical isolates which was depicted by their multi-drug resistance phenotypes, thus emphasizing the need for continuous surveillance of bacterial resistance, institution of antimicrobial resistance stewardship in our hospital and regular screening of ESBLs in clinical isolates to prevent treatment failure.

Keywords: Clinical isolates, esbl, gram negative bacilli, multi-drug resistance

References

  1. Y. Doi, R.A. Bonomo, D.C. Hooper, K.S. Kaye, J.R. Johnson, C.J. Clancy, J.T. Thaden, M.E. Stryjewski, and D. van Duin: “Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.” Clin. Infect. Dis, 64(1):30–S35,2017. doi:10.1093/cid/ciw829.
     Google Scholar
  2. B.T. Tadesse, E.A. Ashley, S. Ongarello, J. Havumaki, M. Wijegoonewardena, I.J. González, and S. Dittrich, “Antimicrobial resistance in Africa: a systematic review.” BMC Infect Dis, 17 (1): 616, 2017. doi:10.1186/s12879-017-2713-1.
     Google Scholar
  3. M. Bassetti, M. Peghin, A. Vena, and D.R. Giacobbe. “Treatment of Infections Due to MDR Gram-Negative Bacteria.” Front. Med, 6:74, 2019. doi:10.3389/fmed.2019.00074.
     Google Scholar
  4. D. Rawat and D. Nair, “Extended-spectrum β-lactamases in Gram Negative Bacteria.” J Glob Infect Dis, 2(3): 263–274, 2010. doi:10/fktqxj.
     Google Scholar
  5. R.H.-P. Dhillon and J. Clark: “ESBLs: A Clear and Present Danger?” Crit Care Res Pract, 2012: 1–11, 2012. doi:10/cm2wj2.
     Google Scholar
  6. K.W. Benner, P. Prabhakaran, and A.S. Lowros, “Epidemiology of Infections Due to Extended-Spectrum Beta-Lactamase–Producing Bacteria in a Pediatric Intensive Care Unit.” J Pediatr Pharmacol Ther, 19 (2): 83–90, 2014. doi:10/gg3qqg.
     Google Scholar
  7. F.J. Giwa, O.T. Ige, D.M. Haruna, Y. Yaqub, T.Z. Lamido, and S.Y. Usman, “Extended ‑ Spectrum Beta ‑ lactamase Production and Antimicrobial Susceptibility Pattern of Uropathogens in a Tertiary Hospital in Northwestern Nigeria.” Ann Trop Pathol, 9: 11–16, 2018. doi:10.4103/atp.atp.
     Google Scholar
  8. O.A. Aboderin, O. Adefehinti, B.W. Odetoyin, A.A. Olotu, I.N. Okeke, and O. Adeodu: “Prolonged febrile illness due to CTX-M-15 extendedspectrum β-lactamase-producing Klebsiella pneumoniae infection in Nigeria.” Afr J Lab Med, 1(1), 2011. doi:10/gffcng.
     Google Scholar
  9. J.D.D. Pitout, P. Nordmann, K.B. Laupland, and L. Poirel, “Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community” J Antimicrob Chemother, 56 (1): 52–59, 2005. doi:10/d4qsfg.
     Google Scholar
  10. R. Ben‐Ami, J. Rodríguez‐Baño, H. Arslan, J.D.D. Pitout, C. Quentin, E.S. Calbo, Ö.K. Azap, C. Arpin, A. Pascual, D.M. Livermore, J. Garau, and Y. Carmeli, “A Multinational Survey of Risk Factors for Infection with Extended‐Spectrum β‐Lactamase–Producing Enterobacteriaceae in Non-hospitalized Patients.” Clin Infect Dis, 49(5): 682–690, 2009. doi:10/d6t5v3.
     Google Scholar
  11. CLSI, “Performance Standards for Antimicrobial Susceptibility Testing,” (2016).
     Google Scholar
  12. A.-P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, C.G. Giske, S. Harbarth, J.F. Hindler, G. Kahlmeter, B. Olsson-Liljequist, D.L. Paterson, L.B. Rice, J. Stelling, M.J. Struelens, A. Vatopoulos, J.T. Weber, and D.L. Monnet, “Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.” Clin Microbiol Infect Dis, 18 (3): 268–281, 2012. doi:10.1111/j.1469-0691.2011.03570.x.
     Google Scholar
  13. R Core Team, “R: A language and environment for statistical computing.” 2019.
     Google Scholar
  14. M.S. Berends, C.F. Luz, A.W. Friedrich, B.N.M. Sinha, C.J. Albers, and C. Glasner, “AMR – An R Package for Working with Antimicrobial Resistance Data.” Microbiology, 2019. doi:10.1101/810622;http://web.archive.org/web/2020070210140 0/https://www.biorxiv.org/content/10.1101/810622v3.
     Google Scholar
  15. F.E. Al-Otaibi, E.E. Bukhari, M. Badr, and A.A. Alrabiaa: “Prevalence and risk factors of Gram-negative bacilli causing blood stream infection in patients with malignancy.” Saudi Med J, 37(9): 979–984, 2016. doi:10/f85jqc.
     Google Scholar
  16. A.Y. Peleg and H. Dc, “Hospital-Acquired Infections Due to Gram-Negative Bacteria.” NEngl J Med, 362:1804–13, 2010. doi:10/bj34wz.
     Google Scholar
  17. B.W. Odetoyin, O. Olaniran, D.O. Afolayan, I.A. Aderibigbe, O. Alaka, and A.A. Onanuga, “Asymptomatic bacteriuria in an apparently healthy population and its relation to hypertension.” Afr J Clin Exp Microbiol, 19 (4): 282, 2018. doi:10/gffcf6.
     Google Scholar
  18. E.U. Israel, E.G. Sylvester, and A. Elijah, “The Use of Antibiotics in a Nigerian Tertiary Health Care Facility,” 1(3): 25-31, 2015.
     Google Scholar
  19. O. Ouchar Mahamat, A. Tidjani, M. Lounnas, M. Hide, J. Benavides, C. Somasse, A.-S. Ouedraogo, S. Sanou, C. Carrière, A.-L. Bañuls, H. Jean-Pierre, Y. Dumont, and S. Godreuil, “Fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in hospital and community settings in Chad.” Antimicrob Resist Infect Control, 8(1): 169, 2019. doi:10/gg3tvq.
     Google Scholar
  20. N. Rahamathullah, S.K. Ahamed Khan, Z. Arshad Khan, A. Farrukh, H.M. Bashir, and A. Ahmad, “Prevalence of extended spectrum beta-lactamase producing Enterobacteriaceae in urine samples from Thumbay hospitals, U.A.E.” Access Microbiol, 1(1A): 434, 2019. doi:10.1099/acmi.ac2019.po0254.
     Google Scholar
  21. P. Sawatwong, P. Sapchookul, T. Whistler, C.J. Gregory, O. Sangwichian, S. Makprasert, P. Jorakate, P. Srisaengchai, S. Thamthitiwat, C. Promkong, P. Nanvatthanachod, M. Vanaporn, and J. Rhodes, “High Burden of Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella pneumoniae Bacteremia in Older Adults: A Seven-Year Study in Two Rural Thai Provinces.” Am J Trop Med Hyg, 100 (4): 943–951, 2019. 100:943–51, doi:10/gg3tvr.
     Google Scholar
  22. B.M. Musa, H. Imam, A. Lendel, I. Abdulkadir, H.S. Gumi, M.H. Aliyu, and A.G. Habib: “The burden of extended-spectrum β-lactamase-producing Enterobacteriaceae in Nigeria: a systematic review and meta-analysis.” Trans. R. Soc. Trop. Med. Hyg, 114(4), 241–248, 2020. doi:10/gg3trs.
     Google Scholar
  23. E.K. Oladipo, J.O. Ogunsola, B.S. Akinade, and E.H. Awoyelu: “Resistance of Clinical Isolates to Generation of Cephalosporins in a Tertiary Hospital in Ogbomoso, South-Western Nigeria.” Res J Microbiol, 10 (2): 76–82, 201, 2015. doi:10.3923/jm.2015.76.82.
     Google Scholar
  24. J. Dantas Palmeira and H.M.N. Ferreira, “Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in cattle production – a threat around the world.” Heliyon, 6 (1): e03206, 2020. doi:10/gg3trx.
     Google Scholar
  25. J. Rodríguez-Baño, B. Gutiérrez-Gutiérrez, I. Machuca, and A. Pascual, “Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.” Clin Microbiol Rev, 31(2): e00079-17, 2018. doi:10.1128/CMR.00079-17.
     Google Scholar
  26. D. Kumar, A.K. Singh, M.R. Ali, and Y. Chander, “Antimicrobial Susceptibility Profile of Extended Spectrum β-Lactamase (ESBL) Producing Escherichia coli from Various Clinical Samples.” Infect Dis, 7: 1–8, 2014. doi:10.4137/IDRT.S13820.
     Google Scholar
  27. S. Vemula and R. Vadde, “Prevalence of ESBL-Producing Klebsiella pneumoniae Isolates in Tertiary Care Hospital.” ISRN Microbiol, 2011: 318–48, 2011.
     Google Scholar
  28. A.-S. Ouédraogo, S. Sanou, A. Kissou, A. Poda, S. Aberkane, N. Bouzinbi, B. Nacro, R. Ouédraogo, P. Van De Perre, C. Carriere, D. Decré, H. Jean-Pierre, and S. Godreuil, “Fecal Carriage of Enterobacteriaceae Producing Extended-Spectrum Beta-Lactamases in Hospitalized Patients and Healthy Community Volunteers in Burkina Faso.” Microb Drug Resist, 23 (1): 63–70, 2017. doi:10/f9k998.
     Google Scholar
  29. D.S. Teklu, A.A. Negeri, M.H. Legese, T.L. Bedada, H.K. Woldemariam, and K.D. Tullu, “Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in Addis Ababa, Ethiopia.” Antimicrob Resist Infect Control, 8 (1): 39, 2019. doi:10.1186/s13756-019-0488-4.
     Google Scholar
  30. Y. Mohammed, G.B. Gadzama, S.B. Zailani, and A.O. Aboderin, “Characterization of extended-spectrum beta-lactamase from Escherichia coli and Klebsiella species from North Eastern Nigeria.” J Clin Diagn Res, JCDR. 10 (2): DC07, 2016.
     Google Scholar
  31. H. Ogefere, P. Aigbiremwen, and R. Omoregie, “Extended-Spectrum Beta-Lactamase (ESBL)–Producing Gram-negative Isolates from Urine and Wound Specimens in a Tertiary Health Facility in Southern Nigeria.” Trop J Pharm Res, 14 (6): 1089, 2015. doi:10/gffcpv.
     Google Scholar
  32. F.S. Codjoe and E.S. Donkor, “Carbapenem Resistance: A Review.” Med Sci, 6 (1): 2017. doi:10/c9zd.
     Google Scholar
  33. Z.D. Pana and T. Zaoutis, “Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?” F1000Research, 7, 2018. doi:10.12688/f1000research.14822.1.
     Google Scholar